AVXL market cap is 150M ONLY due to hope with ALZ...it is not due to all these preclinical orphan designations. If so, then PRAN should not be worth only $5million..they got orphan for hunington disease too.
It all comes down to what AVXL says about ALZ.
they expect much more efficiencies that will start showing this quarter. Under $30 is a great stock to own.
they made 3.12 in Q1....so I assume this year it will be over 13. Current P/E is about 12. Next year will be even lower P/E. Company growing revenue AND earnings both at 100%.
Is it about 10 P/E for 2016 and even less for 2017 ? For a stock growing close to 100%
went over the earning transcript...all great news. Everything up....raised guidance big. Absolutely great earnings and future announcement. Just a bear raid ??
On February 22, 2016, the Board of Directors approved a share repurchase program that authorized the Company to repurchase up to $20 million of shares of stock through August 2016. During the first quarter of 2016, the Company repurchased approximately 30 thousand shares at a total cost of approximately $3.4 million. On May 6, 2016, the Board of Directors approved an amendment to the existing share repurchase program that authorizes the Company to repurchase up to $30 million, representing an increase of $10 million compared to the original authorization, of shares of stock through August 2016.
$8 billion in dept and market cap under $3 billion, with price erosion is not a good combination.
To think, Allergan just did a $10 billion buyback..they could have easily bought some cheap company. ALL pharma companies are really cheap now. But they did not do it.
Pharmas are doing buyback to boost shares, but not acquisitions. Not a good sign.
could be...but longs talking about buyout at $30 is not going to happen. Nobody wants to take on $8 billion of debt. Plus other generics are eating into their profits. Market expects another estimates cut in the summer.
that is why pharmas are going down...too much generic coming in the market, companies killing each other for pricing. There is no quick fix for this....
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Frovatriptan Succinate Tablets 2.5 mg, a generic version of Endo's Frova® Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is used to treat acute migraine headaches in adults.
do a hostile takeover at $25...still almost a double from here.
At some point during summer I see M&A picking up big ....prices too low for this not to happen.
no sir, they are not going bankrupt..go read their earnings transcript.
a LOT is priced in already. Go read their earnings transcript....150 products waiting FDA approval, Lots of exciting products coming later in 2016. A 20% drop in earnings does not equate to 50% drop in stock price. All metrics are VERY cheap. P/B, P/S, P/E.
deeply oversold...average target AFTER Friday warning is about $27-30
Should the company decide to dissolve, the book value per common indicates the dollar value remaining for common shareholders after all assets are liquidated and all debtors are paid.
price to book under 0.5, book value is over $26. Someone will scoop them up quick.
hopefully he is happy.
some stats -
price/book value - 0.5
price/sales - 1
P/E for next year - 2.7
This is CRAZY !!! vrx is overvalued compared this this much more.
CEO needs to buy shares, so do directors.
CEO needs to start looking at strategic - look for suitors, mergers. At 0.5 book value, this is too cheap and a robust pipeline later this year. He already said board is investor friendly. More generic drug companies needs to merge.